One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Viral Clearance Services Market

[ 英語タイトル ] Viral Clearance Services Market - Growth, Trends, and Forecasts (2020 - 2025)

Product Code : MDHC0089168
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 115
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - Charles River Laboratories, Inc.
- Labor Dr. Merk & Kollegen GmbH
- Merck KGaA
- Texcell SA
- WuXi AppTec
- Sartorius AG
- Eurofins Scientific
- Bioscience Laboratories
- Vironova

[Report Description]

The major factors attributing to the growth of the market are the rising need for viral clearance and increasing demand for specialty drugs. Viral clearance service guarantees the safe development of a biological product. Rising demand for virus inactivation or viral removal in products, increasing the need for detection of virus at the early stages of development of the drug, growing research and development activities are factors driving the market.

Furthermore, the integration of technology in the field of biology such as chromatography, and nanofiltration helps in regulating the level of virus clearance. Thus, many pharmaceutical companies are concentrating on heavy investments in research and development activities for streamlining the regulations for viral safety. All such factors boosting the global viral clearance service market. However, lack of approval of outsourcing the preclinical procedures and activities from the various biopharmaceutical organizations is a restraint to the market.

Key Market Trends

Recombinant Proteins Segment is Expected to Dominate the Market During the Forecast Period

Large-scale recombinant protein production is becoming progressively critical for applications in the field of proteomics, structural biology and protein therapeutics. When large quantities of protein need to be produced cells must be cultured in large volume by the implementation of fermentation techniques. As the production of these proteins increases the demand for the viral clearance process also increases.

The major factors driving the growth of the segment are the increasing demand for biopharmaceuticals for treating chronic conditions like diabetes cancers, and these drugs are forging their ways in the field of inflammatory disease management, such as psoriasis, multiple sclerosis, rheumatic diseases, and inflammatory bowel diseases. The introduction of recombinant proteins has revolutionized the development and manufacturing processes of biotherapeutics. The number of recombinant drugs is expected to grow further as multiple biologics and vaccines consisting of recombinant proteins are currently in the pipeline and are expected to get FDA approval. Thus, considering all the above mentioned factors the market is expected to grow.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall viral clearance services market, throughout the forecast period. The largest share is mainly due to the presence of key players and their usage of advanced medical technologies to develop. The rise in the production of recombinant proteins, vaccines and the necessity to keep them risk-free and virus-free, is the major factor for the growth of the market. Furthermore, growing awareness among the population to use biopharmaceuticals and thus increasing demand for viral clearance service.

Competitive Landscape

The viral clearance services market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Charles River, Labor Dr. Merk & Kollegen GmbH, Texcell, Merck KGaA, WuXi AppTec, Sartorius AG, Eurofins Scientific, Bioscience Laboratories, Syngene and Vironova.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Need of Viral Clearance
4.2.2 Rise in Research and Development Funding
4.2.3 Growing Demand for Specialty Drugs
4.3 Market Restraints
4.3.1 Lack of Approval of Outsourcing of Preclinical Procedures
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Method
5.1.1 Viral Removal
5.1.2 Viral Inactivation
5.2 By Application
5.2.1 Recombinant Proteins
5.2.2 Tissue and Blood Derived Products
5.2.3 Vaccines
5.2.4 Others
5.3 By End-User
5.3.1 Biopharmaceuticals
5.3.2 Contract Research Organizations
5.3.3 Academic Research Institutes
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Charles River Laboratories, Inc.
6.1.2 Labor Dr. Merk & Kollegen GmbH
6.1.3 Merck KGaA
6.1.4 Texcell SA
6.1.5 WuXi AppTec
6.1.6 Sartorius AG
6.1.7 Eurofins Scientific
6.1.8 Bioscience Laboratories
6.1.9 Vironova




Recommended reports